SHH · 603939.SS
Yifeng Pharmacy Chain Co., Ltd.
CN¥26.14+CN¥0.94 (+3.73%)
Yifeng Pharmacy Chain Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 1.66% below the high.
Loading market information…
SHH · 601607.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Shanghai Pharmaceuticals Holding Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 11.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Shanghai Pharmaceuticals Holding Co., Ltd’s forward annual dividend is CN¥0.70 per share, paid semi-annual. The forward yield is 4.25% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Shanghai Pharmaceuticals Holding Co., Ltd’s next earnings report is currently expected on Apr 1, 2027, with estimated earnings per share of CN¥0.28. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shanghai Pharmaceuticals Holding Co., Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥73.48B+1.37% vs estimate |
| Q2 2025 | Aug 25, 2025 | CN¥0.84+1.21% vs estimate | CN¥70.83B-1.87% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | CN¥0.36-12.2% vs estimate | CN¥70.76B-4.26% vs estimate |
|---|
| Q4 2024 | Mar 26, 2025 | CN¥0.14-33.33% vs estimate | CN¥65.62B-8.12% vs estimate |
|---|
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥26.14+CN¥0.94 (+3.73%)
Yifeng Pharmacy Chain Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 1.66% below the high.
CN¥5.22+CN¥0.07 (+1.36%)
Jointown Pharmaceutical Group Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 10.62% below the high.
CN¥27.98+CN¥0.20 (+0.72%)
China National Medicines Corporation Ltd.’s quoted price sits in the lower half of its reported 52-week range, 10.26% below the high.
CN¥8.83-CN¥0.04 (-0.45%)
China Meheco Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.78% below the high.
CN¥21.01+CN¥0.07 (+0.33%)
China National Accord Medicines Corporation Ltd.’s quoted price sits in the lower half of its reported 52-week range, 15.76% below the high.
CN¥5.12+CN¥0.09 (+1.79%)
NanJing Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 23.01% below the high.
CN¥9.88+CN¥0.12 (+1.23%)
Zhejiang Int'l Group Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.2% below the high.
CN¥8.53-CN¥0.03 (-0.35%)
HPGC Renmintongtai Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.95% below the high.
